ALDA Pharmaceuticals Corp.
TSX VENTURE : APH

ALDA Pharmaceuticals Corp.

November 30, 2006 10:45 ET

ALDA Pharmaceuticals Corp.: T36'R' Disinfectant Passes All China CDC Tests

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Nov. 30, 2006) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA" or "the Company") has been advised that its T36® Disinfectant has passed a series of tests conducted at the Fujian Bioengineering University College to satisfy the registration requirements of the Chinese Center for Disease Control and Prevention for disinfectant products. These studies verified ALDA's claims of stability, safety and effectiveness against viruses and bacteria, including TB, within the time periods claimed by ALDA. ALDA's agent is now pursuing a manufacturing license in China.

About ALDA

ALDA has developed and markets wide spectrum, non-toxic, non-corrosive, biodegradable infection control products based on its patent-pending T36® technology. Its lead product, T36® Disinfectant, is acknowledged to be effective against all fungi, bacteria, viruses including Avian Flu, SARS, Norwalk Virus, HIV, Legionella and Hepatitis because of its ability to kill polio and TB.

Terrance G. Owen, Ph.D., MBA, President, CEO and Director

ALDA Pharmaceuticals Corp.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information